**RANGER™ ALL Comers SFA Registry**

**Study Design**
Prospective Multicenter all-comer registry, planned enrollment 180 patients
N=172, average lesion length 129 mm

**Patient Characteristics**

<table>
<thead>
<tr>
<th>Average lesion length</th>
<th>Diabetes</th>
<th>Rutherford Class III &amp; higher</th>
<th>TASC C&amp;D lesions</th>
</tr>
</thead>
<tbody>
<tr>
<td>129 mm</td>
<td>35%</td>
<td>78%</td>
<td>48%</td>
</tr>
</tbody>
</table>

**Safety & Efficacy Results at 12 months**

**Patency**
Ranger achieved **84%**
primary patency at 12 months

![Primary Patency Rate Graph](chart)

**Freedom from TLR**
Ranger achieved **89%**
freedom from TLR at 12 months

![Freedom from TLR Graph](chart)
RANGER™ ALL Comers SFA Registry

Patient Outcomes

86% of patients moved up at least 1 Rutherford category at 12M

69% of patients moved up ≥2 Rutherford categories at 12M

Study is sponsored by Klinikum Arnsberg